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Pentameric ligand-gated ion channels (pLGIC) cata-
lyze the selective transfer of ions across the cell
membrane in response to a specific neurotrans-
mitter. A variety of chemically diverse molecules,
including the Alzheimer’s drug memantine, block
ion conduction at vertebrate pLGICs by plugging
the channel pore. We show that memantine has
similar potency in ELIC, a prokaryotic pLGIC, when
it contains an F16’S pore mutation. X-ray crystal
structures, using both memantine and its derivative,
Br-memantine, reveal that the ligand is localized at
the extracellular entryway of the channel pore, and
the pore is in a more closed conformation than
wild-type ELIC in both the presence and absence of
memantine. However, using voltage clamp fluorome-
try we observe fluorescence changes in opposite
directions during channel activation and pore block,
revealing an additional conformational transition not
apparent from the crystal structures. These results
have important implications for drugs such as mem-
antine, which block channel pores.
INTRODUCTION
The family of pentameric ligand-gated ion channels (pLGICs) or
Cys-loop receptors includes nicotinic acetylcholine (nACh),
serotonin (5-HT3), g-aminobutyric acid (GABAA/C), and glycine
(Gly) receptors. These receptors play an important role in fast
synaptic neurotransmission by converting binding of a specific
neurotransmitter that is released from the presynaptic terminal
into a flux of ions across the membrane of the postsynaptic
neuron. pLGICs are integral membrane proteins composed of
an extracellular ligand-binding domain, an ion-conducting trans-
membrane domain, and an intracellular domain; prokaryotic ho-
mologs lack the intracellular domain. Receptor activation occurs
through allosteric coupling between ligand binding and channelStructur
STFODEopening, upon neurotransmitter binding the extracellular domain
is thought to undergo a conformational change that opens
the channel gate and allows the passage of ions. Important prog-
ress in understanding these conformational changes at the
structural level has been made recently with the X-ray crystal
structure determination of the full-length prokaryote homologs
ELIC (Hilf and Dutzler, 2008) and GLIC (Bocquet et al., 2009;
Hilf and Dutzler, 2009), which may represent possible closed
pore and open pore conformations, respectively. In addition, a
crystal structure was also recently determined for GluCl (Hibbs
and Gouaux, 2011), an invertebrate glutamate-gated chloride
channel, which has a truncated intracellular domain to facilitate
crystallization and is thought to also represent an open pore
conformation.
A variety of chemically diverse molecules act as pore blockers
of pLGICs, examples of such molecules are divalent cations,
quaternary ammonium derivatives, aminoadamantanes such
as memantine and rimantadine, lidocaine and quinacrine ana-
logs, tricyclic antidepressants, and the neuroleptic chlorproma-
zine. Many of these channel blockers exert their effects by
plugging the channel pore and inhibiting the flow of ions. For
several decades channel blockers such as these have been
highly instrumental in determining channel pore dimensions,
identifying channel-lining residues, and in single channel studies
(for recent reviews, see Bouzat, 2012; Sine, 2012). In 1977,
Adams first demonstrated that pore blockers can bind both in
open and closed channel states, as described for procaine
blockade of the nACh receptor at the neuromuscular endplate
(Adams, 1977). Recent cocrystal structures of GLIC revealed
important structural insight into the mechanism of open channel
block by showing the channel in an open pore conformation and
bound by quaternary ammonium derivatives, divalent cations, or
a lidocaine analog (Hilf et al., 2010). These structures showed
that these channel blockers bind to the intracellular pore
entryway or midway down the pore-lining M2-helix, and, as
expected, do not cause a significant conformational change in
the open pore.
Despite these recent insights, several important questions
remain unanswered. Previous electrophysiological studies (Buis-
son and Bertrand, 1998) identified two separate binding sites in
the channel pore of a4b2 nACh receptors based on the fractione 22, 1–9, October 7, 2014 ª2014 Elsevier Ltd All rights reserved 1
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Figure 1. An Unusual Phenylalanine Resi-
due Restricts Pore Access in ELIC
(A) Cartoon representation of ELIC with trans-
parent surface overlaid in blue and seen along the
5-fold symmetry axis from the extracellular side of
the channel. The inset shows a detailed sideways
view of the pore-lining M2-helices of two opposing
subunits. Hydrophilic parts of the ion conduction
pathway are colored in green, hydrophobic in
yellow, and charged in orange. The white trans-
parent surface representation highlights the pore
constriction point formed by the 16’F residues (red
sticks).
(B) Sequence alignment of ELIC with human
pLGICs. 16’F residues are found only in nAChR
ε- and g-subunits. 5-HT3 receptors and GABAA
a-subunits contain hydrophobic residues (Leu, Val,
or Ile), whereas GABA receptor b-, g-, and r-sub-
units, GluCl and Gly receptors contain hydrophilic
residues (Thr or Ser). Residues are colored in
shades of blue according to sequence conserva-
tion set at an identity threshold of 40%; 16’ resi-
dues are colored in red.
(C) Structure formulas of the pore blockers used in
this study.
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There is one of these sites that is located near the middle of the
field across the ion pore and may be equivalent to the lidocaine
binding site identified in the open GLIC structure (Hilf et al.,
2010). The second site is located closer to the extracellular
entryway of the channel pore, as pore blockers at this site sense
a significantly smaller fraction of the transmembrane electrical
field (Buisson and Bertrand, 1998). Consequently, Buisson and
Bertrand deduced that channel blockers which inhibit a4b2
nACh receptors can bind to distinct locations within the ion
pore (Buisson and Bertrand, 1998). These data pose several
questions: Where is the second pore blocker site at the extracel-
lular entryway of the channel pore located? What are the struc-
tural determinants of blocker recognition at this binding site?
What is the structural mechanism of blocker trapping in a
closed channel conformation, and do conformational changes
accompany this transition?
As recently demonstrated, ELIC forms cation-selective chan-
nels that are inhibited by divalent cations (Zimmermann et al.,
2012), and a number of compounds that inhibit vertebrate
pLGICs also inhibit ELIC (Thompson et al., 2012), making it
a potentially suitable model for structural and functional
studies of eukaryotic cation-selective pLGICs. In this study,
we demonstrate that the ELIC pore mutant F16’S reliably repli-
cates the blocker sensitivity observed in vertebrate pLGICs.
Using X-ray crystallography, we reveal that memantine, which
is therapeutically used in the treatment of Alzheimer’s disease,
binds in the upper half of the channel pore of the F16’S mutant.
Voltage clamp fluorometry reveals that memantine induces
distinct movements at the outer region of the pore, although
the fact that we observed no obvious structural changes sug-
gests this is an unstable or short-lived memantine-induced
state.STFODE 298
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F16’S Increases the Sensitivity of ELIC to Channel
Blockers
Wepreviously demonstrated that ELIC is activated byGABA and
modulated by benzodiazepines with effects similar to those
observed at eukaryote GABAA receptors (Spurny et al., 2012).
In addition, we previously found that a wide range of known
pLGIC channel blockers also inhibit ELIC (Thompson et al.,
2012). At the structural level, the ELIC pore is unusual in that it
contains a bulky phenylalanine residue at the 16’ position,
located at the extracellular entrance of the channel pore (Fig-
ure 1A). Because of the pentameric symmetry of the protein,
the 16’F residues form a narrow constriction that reduces the
pore radius to less than 1.5 A˚. In eukaryote nACh receptors,
the 16’F residue is found only in the ε- and g-subunits, with
a- and b-subunits containing the smaller hydrophobic Leu resi-
due (Figure 1B). Hydrophobic residues (Leu, Ile, or Val) are also
found in 5-HT3A–E receptors and GABAA receptor a-subunits at
the same location. In contrast, hydrophilic residues (Thr or Ser)
are found in GABAA receptor b- and g-subunits, GABAC recep-
tors, Gly receptors, and the glutamate-activated chloride chan-
nel GluCl. In GLIC, the channel pore contains an Ile residue at
the homologous 16’ position, which is likely to be a less stringent
barrier than phenylalanine, and possibly explains why GLIC has
an enhanced sensitivity for channel blockers when compared to
ELIC (Hilf et al., 2010; Thompson et al., 2012).
To test this hypothesis, we generated a F16’S ELIC mutant
and tested it in Xenopus oocytes and human embryonic kidney
(HEK) cells. In oocytes, we observed a small increase in GABA
half-maximal value of activation (EC50) compared to wild-type
ELIC (6.6 mM versus 1.6 mM, Table 1), as has been previously
reported for a F16’A mutant (Zimmermann and Dutzler, 2011),3
erved
Table 1. Concentration-Response Relationships forWT ELIC and
F16’S in Ca2+-free ND96
GABA pEC50 EC50 (mM) nH n
Wild-type 2.78 ± 0.04 1.6 2.5 ± 0.7 7
F16’S 2.18 ± 0.06 6.6 2.6 ± 0.6 3
Memantine pIC50 IC50 (mM) nH n
Wild-type 3.93 ± 0.02 118 1.7 ± 0.1 5
F16’S 5.08 ± 0.07 8.3 0.9 ± 0.1 4
Rimantadine pIC50 IC50 (mM) nH n
Wild-type 4.27 ± 0.03 54 1.0 ± 0.2 4
F16’S 5.73 ± 0.03 1.9 1.1 ± 0.1 3
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Then, we tested the effect of the F16’S mutation on pore blocker
sensitivity using the aminoadamantane derivatives memantine
and rimantadine as probes (Figure 1C). Rimantadine is an anti-
viral drug that we have previously identified as being one of the
most potent pore-blocking compounds in ELIC (Thompson
et al., 2012). In addition, rimantidine blocks the viral M2 channel
(Schnell and Chou, 2008; Stouffer et al., 2008), and it also inhibits
GLIC and other pLGICs (Alqazzaz et al., 2011). Memantine is
structurally similar to rimantidine; it is clinically used in the treat-
ment of Alzheimer’s disease, likely improving cognition through
channel block of N-methyl-D-aspartate receptors; it also blocks
the pore of a7 nACh receptors with similar or higher potency, but
whether therapeutic effects are mediated through these nACh
receptors is currently debated (Aracava et al., 2005; Oliver
et al., 2001; Rammes et al., 2001; Rogawski and Wenk, 2003).
Testing these compounds on the F16’S mutant revealed that
the sensitivity is enhanced 30-fold for rimantadine and 15-
fold for memantine (Table 1). In HEK cells, the data reveal that
both compounds show mixed inhibition (Figure S1 available
online), as concentration-response curves show an increase in
EC50 and a decrease in the maximum response (Rmax), suggest-
ing possible actions at both the agonist binding site and the
channel pore.
These results point to an important role of 16’F in reducing the
sensitivity of ELIC to pore blockers, possibly by restricting
access to the channel pore. This restriction is relieved in ELIC
F16’S, which displays a sensitivity to pore blockers that is
more similar to eukaryote receptors.
X-Ray Crystal Structures of F16’S ELIC Blocked by
Memantine
To advance our understanding of the molecular determinants of
channel blockers at the structural level, we determined X-ray
crystal structures of ELIC F16’S in complex with memantine or
its brominated derivative Br-memantine (Figure 1C). Such a
bromine substitution greatly facilitates structural studies as
bromine generates an anomalous diffraction signal and aids in
identifying the ligand-binding pose in electron density maps.
The crystal structures of ELIC in complex with memantine or
Br-memantine were determined from X-ray diffraction data at a
resolution of 3.2 A˚ and 3.9 A˚, respectively (crystallographic sta-
tistics are shown in Table 2). These data are of medium resolu-
tion, but in both structures, inspection of the Fourier Fo–Fc
difference map reveals clear peaks at a contour level of 4s atSTFODE
Structurtwo different sites in ELIC, one localizing to the extracellular
domain (Figures 2A–2C) at a site that overlaps with the agonist
binding site and another in the channel pore (Figures 2D–2G).
The binding of memantine at these two distinct sites is further
substantiated by the anomalous difference map of the Br-mem-
antine cocrystal structure, which clearly shows peaks (magenta
mesh in Figures 2C and 2G is contoured at 4.5s for the pore site
and 6s for the agonist binding site) at all five agonist-binding
sites in the extracellular domain and one peak in the channel
pore. Notably, we also observe Fo–Fc difference density near
the 6’ residue in the memantine cocrystal structure, but weaker
Fo–Fc density and no anomalous density in the bromo-meman-
tine structure. Therefore, we believe it could be a cation or water
molecule stabilized near the 6’ residue. The bromine atom in the
Br-memantine molecule is attached at a position that is perpen-
dicular to the amine-moiety (Figure 1C), which allows us to
assign a likely binding pose for this relatively symmetric ligand.
Specifically, in the agonist-binding site we observe that the
anomalous peak is slightly offset toward the () subunit
compared to the simple difference density peak (Figure 2C).
This suggests a likely binding pose for Br-memantine (Figure 2B)
in which the bromine atom points toward Y38 (loop D) and the
amine-moiety is stabilized by cation-p interactions on the (+)
subunit with residues F188 (loop C) and F133 (loop B), which is
similar to the cation-p interactions observed for the ELIC agonist
GABA (Spurny et al., 2012). Little to no conformational change is
observed at the tip of loop C and loop F, which contrasts the
movement of these loops induced by the competitive antagonist
acetylcholine (Pan et al., 2012). The Br-memantine and meman-
tine binding pose strongly overlaps with the GABA binding pose
we recently reported (Spurny et al., 2012), suggesting that mem-
antine can act as a competitive antagonist in the extracellular
ligand-binding site. This result is consistent with earlier observa-
tions that the inhibition of eukaryote nACh receptors by relatively
low concentrations of memantine is voltage-independent and
binds at a site in the extracellular domain (Aracava et al.,
2005). In contrast, inhibitory effects of relatively high concentra-
tions of memantine become voltage-dependent, suggesting an
interaction in the channel pore (Aracava et al., 2005).
In agreement with this observation, we find in the crystal struc-
tures that Br-memantine and memantine bind in the channel
pore (Figures 2D and 2E) at a position that lies between the
13’A and 16’S residues that are located in the extracellular half
of the pore-lining M2-helix (Figure 2F). Clearly, the interpretation
of the electron density ismore complicated at this site (Figure 2G)
given the symmetry mismatch between the pentameric channel
pore and the pyramidal-shaped memantine molecule. Neverthe-
less, we observe that the anomalous difference density is slightly
offset toward the middle of the channel pore compared to the
simple difference density (Figure 2G). This suggests a likely bind-
ing pose for Br-memantine in which the amine-moiety points
toward the hydrophilic upper part of the pore (Figures 2E and
2F). We believe that the opposite orientation, in which the
amine-moiety points toward the hydrophobic middle part of
the pore (9’L and 13’A), is energetically less favorable.
Comparison of the ELIC F16’S memantine-bound structure
with the published crystal structure for wild-type ELIC in
the apo state (Hilf and Dutzler, 2008) (Protein Data Bank
[PDB] code 2VL0) reveals important differences. As expected,2983
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Table 2. Crystallographic Data Collection and Refinement Statistics
ELIC F16’S + Memantine
ELIC F16’S + Br-Memantine
(Data Set 1)
ELIC F16’S + Br-Memantine
(Data Set 1 and 2) ELIC F16’S apo
Crystallographic Statistics
Beamline X06A (SLSa) X06A (SLSa) X06A (SLSa) X06A (SLSa)
Date of collection September 25, 2012 November 10, 2012 November 10, 2012 March 30, 2014
Wavelength (A˚) 0.9999 0.91946 0.91946 0.9999
Spacegroup P21 P21 P21 P21
a,b,c (A˚) 105.48, 265.28, 111.10 106.50, 266.09, 112.18 106.33, 266.05, 111.92 105.9, 264.97, 111.33
b () 110.28 107.70 107.78 108.82
Resolution limits (A˚) 49.47  3.2 (3.37  3.2) 49.83  3.90 (4.11  3.90) 49.73  5.0 (5.27  5.0) 48.96  3.60 (3.79  3.60)
Rmerge (%) 9.0 (89.8) 13.7 (93.6) 11.5 (29.2) 14.7 (99.3)
<I/s > 12.5 (1.5) 8.7 (1.5) 18.6 (9.3) 8.4 (1.5)
Multiplicity 3.5 (3.3) 4.9 (4.9) 14.1 (13.3) 3.9 (4.0)
Completeness (%) 99.8 (99.7) 99.3 (95.5) 99.9 (100.0) 99.9 (100.0)
Total number of reflections 328,872 (45,224) 260,800 (36,496) 362,083 (49,830) 260,535 (39,343)
Number unique reflections 93,823 (13,615) 53,624 (7,432) 25,615 (3,740) 66,992 (9,751)
Anomalous completeness 97.5 (92.2) 99.8 (99.9)
Anomalous multiplicity 2.5 (2.5) 7.1 (6.6)
Refinement and Model Statistics
Rwork (%) 19.9 20.21 22.01
Rfree (%) 25.22 24.99 26.34
Rmsd bond distance (A˚) 0.013 0.009 0.009
Rmsd bond angle () 1.71 1.56 1.589
Ramachandran analysis
Outliers (%) 2.95 1.61 2.30
Favored (%) 90.95 91.28 90.36
Average B factors (A˚2)
Protein 120.414 142.443 118.71
Ligand 107.953 131.125
MolProbity score (%) 83 95 91
aSwiss Light Source
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residue causes a considerable widening of the channel pore
at this position (Figures 3A and 3B), thereby relieving the
restricted pore access imposed by the phenylalanine side
chains. Consequently, the pore radius increases from <2 A˚ at
the 16’F position to 4 A˚ following 16’S substitution (Figure 3C),
a change that is sufficient to permit access of the blocker to
the binding site just below the 16’S position. Remarkably, we
also observe that the pore widening is partially compensated
by a contraction of the M2-helices around the memantine
molecule. This becomes apparent upon superposition of F16’S
ELIC and wild-type apo ELIC (Figures 3D and 3E), which shows
an inward movement of the M2-helices at their extracellular
ends, and a 2 tilt over residue 6’T. An important question is
whether this inward movement of the M2-helices is caused by
the F16’S mutation, memantine binding, or a combination of
both. To address this question, we determined the crystal struc-
ture of F16’S apo structure at a resolution of 3.5 A˚. In the F16’S
apo structure, we observe an inward movement of the M2-
helices that is similar to F16’S ELIC with memantine bound.
This result suggests that the observed movement in F16’SSTFODE 298
4 Structure 22, 1–9, October 7, 2014 ª2014 Elsevier Ltd All rights resELIC with memantine bound is caused in part by the mutation
rather than ligand binding.
Conformational Pore Dynamics upon Channel Block by
Memantine
To determine if memantine causes a conformational change that
is not apparent from the structural data, we used voltage clamp
fluorometry (VCF) on Xenopus oocytes expressing ELIC F16’S.
This technique involves the incorporation of a cysteine residue
into a domain of interest and labeling it with a sulfhydryl-reactive,
environmentally sensitive fluorescent dye. Possible changes in
fluorescence due to movement of the domain to a different local
environment are then simultaneously recorded with channel
currents. This approach permits a direct correlation between
conformational changes of the labeled domain and channel
gating, measured in real time. To this end, we engineered the
F16’S mutation in the background of an otherwise cysteine-
free channel, except for a cysteine residue incorporated at the
19’ position, which is localized at the top of the M2-helix (Fig-
ure 4A). Fluorophores attached to the homologous 19’C muta-
tion have been exploited in VCF studies on other pLGICs, where3
erved
Figure 2. Crystal Structures of ELIC F16’S
with Memantine Bound
(A) Sideways cartoon view of X-ray crystal struc-
ture of ELIC F16’S in complex with bromo-
memantine. Br-memantine is shown in sphere
representation (orange is carbon, blue is nitrogen,
and magenta is bromine).
(B) Detailed view of molecular recognition of Br-
memantine in the agonist-binding site formed at
the extracellular interface between the (+) subunit
and () subunit. Conserved aromatic residues of
the agonist-binding site are highlighted in yellow
stick representation.
(C) Experimental electron densities observed at
this site for Br-memantine and memantine
(molecules are shown in ball and stick repre-
sentation). Fo–Fc difference density peaks are
shown as a green mesh and at a contour level
of 4s. The anomalous difference density peak
is shown as a magenta mesh and at a contour
level of 6s.
(D) Top cartoon view of ELIC F16’S in complex with
Br-memantine. The inset in (E) shows a detailed
view of a single Br-memantine molecule bound in
the pore of the channel.
(F) Sideways view of pore-lining M2-helices from two opposing subunits. The Br-memantine molecule is bound at the extracellular entryway of the channel
pore between the 13’A and 16’S residues.
(G) Experimental electron densities observed for Br-memantine and memantine in the pore site. Fo–Fc difference density peaks are shown as a green mesh (4s)
and anomalous difference density as a magenta mesh (4.5s).
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M2 domain during channel gating (Pless et al., 2007; Wang
et al., 2010).
VCF recordings were carried out in Ca2+-containing ND96 and
showed that unlabeled F16’S+S19’C ELIC has a sensitivity to
GABA (EC50 = 39 mM, Table 3) and the full agonist propylamine
(Zimmermann and Dutzler, 2011) (EC50 = 740 mM), that are com-
parable to wild-type (21 mM and 446 mM, respectively [Spurny
et al., 2012; Zimmermann and Dutzler, 2011]). In addition,
F16’S+S19’C has sensitivity to memantine that is comparableSTFODE
Structurto F16’S ELIC (half-maximal value of inhibition [IC50]= 54 mM,
Table 3). After fluorescent labeling of F16’S+S19’C ELIC
with methanethiosulfonate-rhodamine (MTSR), the agonist and
blocker sensitivities also remain relatively similar (EC50 GABA =
50 mM, EC50 propylamine = 870 mM, IC50 memantine = 91 mM,
Table 3). For VCF recordings, we applied 150 mM memantine
(pore blocker) or 20 mM propylamine (full agonist). For meman-
tine, we observe a negative deflection in the fluorescence (Fig-
ure 4B, DFmax = 1.56 ± 0.81%, n = 6), whereas the full agonist
propylamine evokes a positive deflection in the fluorescenceFigure 3. Pore Closure Traps a Memantine
Molecule
(A and B) Surface representation of the extracel-
lular entryway of the ELIC channel pore for WT
ELIC apo (Hilf and Dutzler, 2008) (red transparent
surface, A) and ELIC F16’S (blue transparent sur-
face, B). 16’ residues are shown as sticks. Mem-
antine is shown in orange sticks.
(C) Pore radius calculated for WT ELIC apo (red),
ELIC F16’S (blue), and GLIC (Bocquet et al., 2009;
Hilf and Dutzler, 2009) (green). Red and blue dots
highlight the difference in pore radius near 16’
residues. The orange arrow indicates the approx-
imate location of the memantine binding site in the
channel pore.
(D) Cartoon representation of the a helical back-
bone for WT apo and F16’S ELIC. This cartoon
illustrates that the pore widening near F16’S is
partially compensated by a contraction of the pore
domain around the memantine molecule. The dis-
tance movement of the M2-helix is 0.6 A˚ as mea-
sured between the Ca atoms of the 16’ residues.
(E) Sideways view of the ELIC pore highlights a 2
tilt of the M2-helices around the 6’T residue.
2983
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Figure 4. Voltage Clamp Fluorescence Shows Conformational
Change of M2 by Memantine
(A) Ribbon representation of pore-lining M2-helices and memantine shown in
sphere representation. The red sphere indicates the location of the fluorophore
attached to 19’C.
(B) VCF recording of ELIC F16’S fluorescently labeled at S19’C using MTSR.
Channels were activated with 20mMof the agonist propylamine (Zimmermann
and Dutzler, 2011) and blocked with 150 mM memantine. Fluorescence de-
flections are in opposite directions during channel opening compared to pore
block.
Table 3. Concentration-Response Relationships for
F16’S+S19’C ELIC before and after Fluorescent Labeling
Ca2+-Containing ND96
GABA pEC50 EC50 (mM) nH n
F16’S + S19’C unlabeled 1.41 ± 0.07 39 1.5 ± 0.3 4
F16’S + S19’C labeled 1.30 ± 0.02 50 4.2 ± 1.6 4
Memantine pIC50 IC50 (mM) nH n
F16’S + S19’C unlabeled 4.27 ± 0.01 54 0.8 ± 0.1 5
F16’S + S19’C labeled 4.04 ± 0.16 91 1.0 ± 0.1 5
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MTSR responds with an increase in quantum efficiency as the
hydrophobicity of its local environment increases (Dahan et al.,
2004). Consequently, it can be deduced that the 19’ residue
moves to a more hydrophobic environment during channel
opening and a more hydrophilic environment during pore block
by memantine. From the perspective of published ELIC and
GLIC crystal structures, the agonist-induced local change could
be interpreted in the context of an outwardM2-tilt during channel
opening (Bocquet et al., 2009; Hilf and Dutzler, 2009). The struc-
tural basis of the memantine-induced conformational change is
unclear, although it must be different to that produced by the
agonist. As the memantine-induced conformational change is
not apparent in the crystal structure, we conclude that it repre-
sents either a subtle conformational change or an unstable or
short-lived state that is not amenable to crystallization.STFODE 298
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Understanding the structural determinants of pore block in open
and closed conformations of a channel is fundamental in ion
channel biology. In this study, we have revealed the crystal struc-
ture of a prokaryote model ion channel ELIC captured in a pore-
blocker bound conformation. We find that the pore blocker
memantine, which is clinically used as an Alzheimer’s disease
drug, binds at a site in the extracellular entryway of the pore (Fig-
ure 5), which likely corresponds to a previously identified periph-
eral site that senses only a small fraction of the transmembrane
electrical field (Buisson and Bertrand, 1998). VCF demonstrated
that memantine elicited a conformational change distinct from
that of a channel opener at the extracellular region of the M2
domain, although no alterations in this region were apparent in
the crystal structure. We infer that memantine induces a short-
lived or unstable state, which differs from that induced by an
agonist. This result is important in understanding the mecha-
nisms of action of pore-binding drugs.
Our finding emphasizes the conformational flexibility of the
channel pore and demonstrates a closed conformation to the
currently known collection of conformational states of both
ELIC and other pLGICs, which include an open state of an L9’-
and F16’-mutated ELIC (Gonzalez-Gutierrez et al., 2012), GLIC
at acidic pH (Bocquet et al., 2009; Hilf and Dutzler, 2009), and
GluCl with ivermectin and glutamate (Hibbs and Gouaux,
2011), as well as different possible closed states, namely apo
ELIC (Hilf and Dutzler, 2008), the locally closed state as observed
in cysteine-crosslinked GLIC (Prevost et al., 2012) and the pre-
sumed resting or closed state of GLIC at neutral pH (Sauguet
et al., 2014). The insights derived from our study on ELIC likely
extend to the other members of the pLGIC family and have impli-
cations for the rational design of new pore blocker drugs with
therapeutic importance.
EXPERIMENTAL PROCEDURES
Two-Electrode Voltage Clamp Recordings
For electrophysiological recordings from Xenopus oocytes, stage V–VI
oocytes were injected with 10 ng ELIC mRNA and incubated at 18C until
the day of recording. ELIC cDNA was cloned into the pGEM-HE expression
vector and mRNA was transcribed in vitro using the mMESSAGE mMACHINE
T7 transcription kit (Ambion) as previously described (Spurny et al., 2012).
Mutants were engineered using a QuikChange strategy (Stratagene) and veri-
fied by sequencing.
Using two-electrode voltage-clamp, Xenopus oocytes were clamped at
60 mV using an OC-725 amplifier (Warner Instruments), Digidata 1322A,
and the Strathclyde Electrophysiology Software Package (Department of
Physiology and Pharmacology, University of Strathclyde, UK). Currents were
recorded at 5 kHz and filtered at a frequency of 1 kHz. Micro-electrodes3
erved
Figure 5. Model of Pore Block
Schematic illustration of the mechanism of open channel block compared to
closed channel block. The pore-lining M2-helices are represented as rectan-
gles with hydrophilic regions in green, hydrophobic in yellow, and charged in
orange. In the open channel state, blockers can bind at a site for divalent
cations (Hilf et al., 2010) (illustrated as a blue sphere), which is localized near
the ion selectivity filter (1’ residue). Larger molecules, such as Br-lidocaine
(Hilf et al., 2010) (illustrated as a magenta sphere) also bind the open channel
state at a site midway the ion conduction pathway, which is localized near the
9’ residue. In the blocker-trapped ELIC state, pore blockers such as mem-
antine (illustrated as a red sphere) can bind at a site near the extracellular
entryway of the channel pore, which is localized between 13’ and 16’ residues.
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using a two stage horizontal puller (P-87, Sutter Instrument) and filled with
3 M KCl. Pipette resistances ranged from 1.0–2.0 MU. Because Ca2+ has
been shown to inhibit the ELIC pore (Zimmermann et al., 2012), and this could
complicate the interpretation of other pore blocking effects, oocytes were
perfused with Ca2+-free ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM
HEPES, pH 7.5) at a constant rate of 12 ml/min. Drugs were dissolved in the
same saline and applied to oocytes using a simple gravity fed system cali-
brated to run at the same rate. Inhibition by test compounds was measured
at the GABA EC50 for each mutant receptor.
Analysis and curve fitting was performed using Prism v4.03 (GraphPad Soft-
ware, San Diego, California, USA). Concentration-response data for each
oocyte were normalized to the maximum current for that oocyte. The mean
and SEM for a series of oocytes were plotted against agonist or antagonist
concentration and iteratively fitted to the following equation:
IA = Imin +
Imax  Imin
1+ 10nHðlog A50 log AÞ
;
where A is the concentration of ligand present; IA is the current in the presence
of ligand concentrationA; Imin is the current whenA = 0; Imax is the current when
A = N, A50 is the concentration of A which evokes a current equal to (Imax +
Imin)/2; and nH is the Hill coefficient.
FLEXstation Experiments
These were performed as previously described (Price and Lummis, 2005).
Briefly, cells were gently rinsed twice with buffer (10 mM HEPES, 115 mM
NaCl, 1 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, pH 7.4) and
100 ml fluorescent membrane-potential sensitive dye (Molecular Devices)
added. Cells were then incubated at room temperature for 45 min before
assay. Fluorescence was measured in a FLEXstation (Molecular Devices)
every 2 s using the acquisition software SOFTmax PRO v4.3. (Molecular
Devices) GABA (0.3300 mM) or buffer was added after 20 s. Memantine
(1300 mM) was preincubated for 5 min before assay.
Voltage Clamp Fluorometry
VCF experiments were carried out as previously described (Pless et al., 2007).
In brief, an inverted Nikon Eclipse TE300 microscope (Nikon Instruments) was
equipped with a high-Q TRITC filter set (Chroma Technology), and a LambdaSTFODE
StructurLS 175-W xenon arc lamp was used as a light source. Excitation and emission
wavelengths were selected using a Lambda 10-2 unit (Sutter Instruments). A
Plan Fluor X40 objective lens (Nikon Instruments) was used to focus light on
the dark pole of the oocyte, and fluorescent light was detected using a
PMT400 photomultiplier tube (IonOptix) connected to the side port of the
microscope. Oocytes were perfused with regular ND-96 solution (96 mM
NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.5). Ca
2+
was included in recording solution for VCF experiments as this accelerates
the kinetics of ELIC (Spurny et al., 2012) and reduces possible photobleaching
during the time course of our experiments. VCF recordings were done in a
custom recording chamber as described (Dahan et al., 2004) using an auto-
mated Valvebank 8 perfusion system (AutoMate Scientific). Fluorescence
and current signals were simultaneously acquired at a sampling frequency
of 200 Hz using a Digidata 1322A interface and Clampex 9.2 software (Molec-
ular Devices). The fluorescence signal was digitally filtered at a frequency of
12 Hz with an 8-pole Bessel filter for display and analysis. Electrodes for
VCF recordings were filled with 3 M KCl and had a resistance near 1 MU.
ELIC cysteine mutants for VCF experiments were constructed in the back-
ground of cysteine-free ELIC (C300S+C313S), which has functional properties
that are indistinguishable from wild-type (WT) ELIC. Oocytes injected with
ELIC mRNA were fluorescently labeled 35 days after injection by a 1 min
incubation in a solution containing 10 mM methanethiosulfonate-rhodamine
(MTSR, Toronto ResearchChemicals) in ND96. The oocyteswere thenwashed
three times in ND96 and stored in the absence of light at 18C until the start of
recording.
Protein Expression and Crystallization
The cDNA encoding ELIC F16’S was constructed using a QuikChange (Strata-
gene) method and verified by sequencing (LGCGenomics). ELIC F16’S protein
was expressed and purified as previously described for WT ELIC with minor
modifications (Spurny et al., 2012, 2013). Briefly, ELIC F16’S was expressed
as an N-terminal fusion to maltose binding protein (MBP) in the C43 E. coli
strain. Membranes were solubilized with 2% anagrade n-undecyl-b-D-malto-
side (UDM; Anatrace) and affinity purified on amylose resin (New England
Biolabs), followed by cleavage with 3CV protease to remove MBP. ELIC
F16’S was purified further on a Superdex 200 10/300 GL (GE Healthcare)
column equilibrated with buffer containing 10 mM Na-phosphate (pH 8.0),
150 mM NaCl, and 0.15% UDM. Peak fractions corresponding to cleaved
pentameric ELIC F16’S were pooled, concentrated, and supplemented with
E. coli total lipid extract (Avanti Polar Lipids) prior to crystallization.
Crystallization of ELIC F16’S apo and complexes with memantine (Sigma-
Aldrich) or bromo-memantine (synthesis described below) was carried out at
4C by vapor diffusion of sitting drops. The crystallization buffer was com-
posed of 200 mM ammonium sulfate, 50 mM (N-(2-acetamido)iminodiacetic
acid) pH 6.5, and 9%12% PEG4000. Crystals of ELIC F16’S in complex
with memantine or bromo-memantine were obtained in the presence of
10 mM memantine and 8 mM bromo-memantine. Crystals were harvested
by adding 30%glycerol as a cryoprotectant to themother liquor and immersed
in liquid nitrogen.
Structure Determination and Refinement
X-ray diffraction data sets for ELIC F16’S apo and complexes with memantine
or bromo-memantine were collected at beamline X06A of the Swiss Light
Source (Paul Scherrer Institute) and reached resolution limits of 3.5 A˚, 3.2 A˚,
and 3.9 A˚, respectively. For the ELIC structure in complexwith bromo-meman-
tine, we used the 3.9 A˚ data for structure refinement (data set 1 in Table 2). To
aid the interpretation of ligand density, we calculated anomalous difference
density maps using reflections to 5 A˚ from a higher redundancy data set ob-
tained by merging data from different crystals (data set 1 and 2 in Table 2).
Full crystallographic statistics are reported in Table 2. Data integration was
done in XDS (Kabsch, 2010) and scaling in SCALA (Winn et al., 2011). Model
building and refinement was carried out by iterative cycles of manual
rebuilding in COOT (Emsley et al., 2010) and refinement in PHENIX (Adams
et al., 2010). AutoNCS in PHENIX was used to automatically detect noncrys-
tallographic symmetry (NCS) restraints, which were maintained during refine-
ment for an entire subunit per NCS group. There was one Translation/
Libration/Screw body that was assigned per subunit. Ligand restraints for
memantine and bromo-memantine were generated using ELBOW in the2983
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Figure 6. Synthetic Scheme for Bromo-Memantine
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2010), and all figures were prepared using PyMOL. The analysis of pore dimen-
sions was carried out using HOLE (Smart et al., 1996).
Synthesis of Bromo-Memantine
The synthetic scheme for bromo-memantine is presented in Figure 6. To a
solution of hydroxyadamantyl amine hydrochloride 1 (200 mg. and 0.86 mmol)
in HBr (5 ml), LiBr (3 eq., 2.59 mmol, 225 mg) was added at room temperature.
The reaction mixture was stirred at room temperature for 16 hr. Upon
completion of the reaction (liquid chromatography-tandem mass spectrom-
etry [LC-MS] and thin layer chromatography monitoring), the reaction mixture
was basified at 0C with 1N NaOH and extracted with CH2Cl2 (43, 50 ml). The
combined organic layers were dried over MgSO4, filtered, and evaporated to
afford 3-bromoadamantylamine derivative 2 as a free base that was used in
the next step without further purification. To crude material 2, a solution of
4N HCl in dry dioxane (3 ml) was added at room temperature. The mixture
was stirred at room temperature, for 4 hr then 1 hr at 0C. The solid that precip-
itated was collected by filtration, washed with ether, and dried under high
vacuum to afford the targeted 3-bromo-5,7-dimethyl adamanly-1-amine hy-
drochloride 3 (114 mg, 44.8%) as a colorless powder. Compound 3 or
3-bromo-5,7-dimethyladamantyl-1-amine hydrochloride, is a racemic mixture
termed bromo-memantine throughout this manuscript and was identified and
characterized through LC-MS and 1H-NMR. 1H-NMR (300 MHz, DMSO-d6):
d = 0.91 (s, 6H); d = 1.12 (d, J = 12 Hz., 1H); d = 1.25 (d, J = 12 Hz., 1H); d =
1.43 (d, J = 12 Hz., 2H); d = 1.52 (d, J = 12 Hz., 2H); d = 1.89 (d, J = 12 Hz.,
2H); d = 1.95 (d, J = 12 Hz., 2H); d = 2.22 (s, 2H); and d = 8.09 (s, br., 3H).
ACCESSION NUMBERS
Structure factors and coordinates for ELIC F16’S apo and complexes with Br-
memantine or memantine are deposited in the Protein Data Bank with acces-
sion codes 4TWH, 4TWD, and 4TWF, respectively.
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Supplemental Information includes one figure and three 3D molecular struc-
tures and can be found with article online at http://dx.doi.org/10.1016/j.str.
2014.07.013.
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